These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 7687515)
1. CYFRA 21-1. A new marker in lung cancer. Stieber P; Hasholzner U; Bodenmüller H; Nagel D; Sunder-Plassmann L; Dienemann H; Meier W; Fateh-Moghadam A Cancer; 1993 Aug; 72(3):707-13. PubMed ID: 7687515 [TBL] [Abstract][Full Text] [Related]
2. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer. Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383 [TBL] [Abstract][Full Text] [Related]
3. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Kulpa J; Wójcik E; Reinfuss M; Kołodziejski L Clin Chem; 2002 Nov; 48(11):1931-7. PubMed ID: 12406978 [TBL] [Abstract][Full Text] [Related]
4. [CYFRA 21-1: a new marker of epidermoid cancer of the bronchi. Comparison with 3 other markers]. Pujol JL; Grenier J; Ray P; Gautier V; Aouta MD; Michel FB Presse Med; 1993 Jun; 22(22):1039-42. PubMed ID: 7692432 [TBL] [Abstract][Full Text] [Related]
5. Assessment of serum CYFRA 21-1 in lung cancer. Muraki M; Tohda Y; Iwanaga T; Uejima H; Nagasaka Y; Nakajima S Cancer; 1996 Apr; 77(7):1274-7. PubMed ID: 8608502 [TBL] [Abstract][Full Text] [Related]
6. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions. Seemann MD; Beinert T; Fürst H; Fink U Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925 [TBL] [Abstract][Full Text] [Related]
7. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study. Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259 [TBL] [Abstract][Full Text] [Related]
8. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer. Stieber P; Dienemann H; Hasholzner U; Müller C; Poley S; Hofmann K; Fateh-Moghadam A Eur J Clin Chem Clin Biochem; 1993 Oct; 31(10):689-94. PubMed ID: 7507359 [TBL] [Abstract][Full Text] [Related]
9. Biomarkers in the lung cancer diagnosis: a clinical perspective. Li X; Asmitananda T; Gao L; Gai D; Song Z; Zhang Y; Ren H; Yang T; Chen T; Chen M Neoplasma; 2012; 59(5):500-7. PubMed ID: 22668014 [TBL] [Abstract][Full Text] [Related]
10. High levels of cytokeratin 19 fragments but no evidence of cytokeratins 1, 2, 10/11, 14 or filaggrin in the serum of squamous cell lung carcinoma patients. Miédougé M; Devys A; Simon M; Rouzaud P; Salama G; Reyre J; Pujazon M; Carles P; Serre G Tumour Biol; 2001; 22(1):19-26. PubMed ID: 11054023 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of Cyfra 21-1 as a marker for lung cancer. Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188 [TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer. Lee JH; Chang JH Chest; 2005 Oct; 128(4):2298-303. PubMed ID: 16236887 [TBL] [Abstract][Full Text] [Related]
13. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098 [TBL] [Abstract][Full Text] [Related]
14. CYFRA 21-1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels. Molina R; Agusti C; Mañe JM; Filella X; Jo J; Joseph J; Giménez N; Estapé J; Ballesta AM Int J Biol Markers; 1994; 9(2):96-101. PubMed ID: 7523548 [TBL] [Abstract][Full Text] [Related]
15. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer. Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815 [TBL] [Abstract][Full Text] [Related]
16. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China. Song WA; Liu X; Tian XD; Wang W; Liang CY; Zhang T; Guo JT; Peng YH; Zhou NK Chin Med J (Engl); 2011 Oct; 124(20):3244-8. PubMed ID: 22088515 [TBL] [Abstract][Full Text] [Related]
17. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318 [TBL] [Abstract][Full Text] [Related]
18. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients. Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320 [TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of chest radiography, computed tomography and tumour markers in the differentiation of malignant from benign solitary pulmonary lesions. Seemann MD; Seemann O; Dienemann H; Schalhorn A; Prime G; Fink U Eur J Med Res; 1999 Aug; 4(8):313-27. PubMed ID: 10471543 [TBL] [Abstract][Full Text] [Related]
20. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer. Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]